AI assistant
Werewolf Therapeutics, Inc. — Director's Dealing 2021
May 4, 2021
34192_dirs_2021-05-04_e2ad6ab1-d96a-441d-8e93-e4f8e9f5c3f0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Werewolf Therapeutics, Inc. (HOWL)
CIK: 0001785530
Period of Report: 2020-08-03
Reporting Person: Lubman Ellen (Chief Business Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-08-03 | Stock Option (right to buy) | $1.56 | A | 145531 | Acquired | 2030-08-02 | Common Stock (145531) | Direct |
| 2020-12-08 | Stock Option (right to buy) | $4.77 | A | 118781 | Acquired | 2030-12-07 | Common Stock (118781) | Direct |
| 2021-04-30 | Stock Option (right to buy) | $16.00 | A | 48455 | Acquired | 2031-04-29 | Common Stock (48455) | Direct |
Footnotes
F1: The option was granted on August 3, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and 2.0833% of the shares vesting each month thereafter through December 8, 2024.
F2: The option was granted on December 8, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and 2.0833% of the shares vesting each month thereafter through December 8, 2024.
F3: The option was granted on April 30, 2021. The shares underlying the option vest over four years in equal monthly installments through April 30, 2025.